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Mediators of Inflammation well on track to connect Molecular
Pharmacology and Therapeutics
Mediators ofInflammation has now completed its
first three years of publication and this prompts me
to address our journal’s readers.
First of all, let me recount some of the very good
things that have marked these three years. There has
been an appreciable increase in the submission of
unsolicited articles. It is also a good sign that, follow-
ing the publication of their first paper, several au-
thors have submitted a second paper to our journal.
The constant flow of submissions has made the
regular bimonthly appearance possible. This, in turn,
has contributed to the fact that Mediators ofInflam-
mation has qualified for a listing in Current Contents
and being covered by major abstracting services,
despite its short existence. Authors can thus be
assured of a broad readership of their articles.
All of this would not have been possible without
the permanent and creative assistance of members of
the Editorial Board and external referees. would
like to take the opportunity of thanking those mem-
bers who are retiring from the journal and to wel-
come those who, following our invitation, are joining
the Editorial Board. The enlargement of the Editorial
Board has become necessary to enable us to cope
with the flexible profile of our journal.
would like to elaborate a little on what we
understand by the flexible profile of our journal. Ever
since its launch, in contrast with several more special-
ized journals that focus on a particular class of
inflammatory mediator (e.g. eicosanoids, PAF, hista-
mine, cytokines, etc.), the inherent power of Media-
tors ofInflammation has been obvious. It is expected
to continue flourishing even when some individual
mediators take a back seat (as they inevitably do) and
are replaced by newly emerging ones. Indeed, the
scene changes very rapidly. The declining interest in
prostanoids and the continuing progress of cytokines
and adhesion molecules exemplify the fluctuations
of the field. Our journal easily keeps pace with these
and related trends.
It is also important to devote a few words to the
subtitle of the journal. The present issue is the first
to carry on its masthead the subtitle MolecularPhar-
macology and Therapeutics. The introduction of this
subtitle does not announce a new departure for our
journal, but simply reflects its true nature. Many
scientific domains are well represented in our jour-
nal, including experimental disciplines (pharmacol-
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ogy, immunology, cell biology, etc.) a, well a. con-
tributions from clinical areas. Clearly, this indicates
that mediators of the inflammation process are of
pivotal importance in a great many fields of the life
sciences, and that our journal is on its way to devel-
oping into a keynote forum for disseminating know-
ledge in all these domains.
The backbone of our journal remains the publica-
tion of full-length original Research Articles. How-
ever, as echoes from readers indicate the usefulness
of InvitedReviews, we shall be continuing our efforts
to publish this kind of paper. Also we wish to
introduce two new categories of paper, namely Short
Communications and Letters to the Editors. For the
scope and style of these, we refer the reader to the
revised Instructions to Authors.
One of the original goals set by Mediators of
Inflammation was for our journal to become a prime
forum of the highest quality in the field of research
on inflammation. We are still some distance from this
goal, mainly because the scientific standard of the
research articles was occasionally variable. Now that
the flow of submitted articles has increased appreci-
ably, it is appropriate to raise the standards for
acceptance, made necessary by the fierce competi-
tion between journals for really excellent papers.
Finally, would like to emphasize two features,
neither of which is unfamiliar to contributors and
readers of our journal. One of these is speed in
refereeing and publishing. In close collaboration
with the publishers, Rapid Communications of Ox-
ford, all possible efforts will be continued to serve
the research community in disseminating the latest
results with the highest speed. The other feature
maintained by our journal is the Jarts pLiple of
the mediators’ concept. This principle of duality,
namely that mediators can exert both harmful and
beneficial functions in health and disease, gathers
momentum in our journal. When some of the articles
advocating this principle appear to be controversial,
they should provoke counteropinions amongst col-
leagues. Such Debate Articles are to be encouraged.
In the coniing years, my colleague Editors and
look forward to receiving the best and latest results
from the scientific community of the inflammation
field.
Ivan L. Bonta
Editor-in-Chief
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